Patrys Company Description

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases.

It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs.

The company was incorporated in 2006 and is based in Nedlands, Australia.

Patrys Limited

Country	Australia
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	James Campbell

Contact Details

Address: 168 Stirling Highway Nedlands, Washington 6009 Australia
Phone	61 8 6165 8858
Website	patrys.com

Stock Details

Ticker Symbol	PAB
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000PAB9
SIC Code	2836

Key Executives

Name	Position
Johnathon Busing C.A.	Joint Company Secretary
Kieran Witt C.A.	Joint Company Secretary